3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
3
Leukemia
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Fallopian Tube Neoplasms
1
Congenital Abnormalities
1
Central Nervous System Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
34
Etoposide
25
Doxorubicin
20
Carboplatin
20
Vincristine
19
Isotretinoin
19
Topotecan
17
Temozolomide
17
Irinotecan
16
Filgrastim
16
Melphalan
15
Cisplatin
15
sargramostim
14
Radiotherapy
14
Granulocyte-Macrophage Colony-Stimulating Factor
13
3-Iodobenzylguanidine
12
dinutuximab
11
Peripheral Blood Stem Cell Transplantation
11
naxitamab
9
Thiotepa
9
Magnetic Resonance Spectroscopy
9
humanized 3F8 anti-GD2 monoclonal antibody
7
Granulocyte Colony-Stimulating Factor
7
Busulfan
7
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Ifosfamide
6
Antilymphocyte Serum
6
fludarabine phosphate
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroblastoma
×
IL32 protein, human
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts